Investors
Eyevensys is proud to receive funding from investors committed to helping drive innovation in the health sector. Our investors include:

Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference   

 Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference    1667 2500 Eyevensys

Paris, France, and Cambridge, Mass., United States, May 11, 2022 — Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the…

Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

 Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting 2500 1667 Eyevensys

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its…

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

 Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical 1920 1080 Eyevensys

Manufacturing of Eyevensys’ core ocular device and electrical pulse generator technology covered under a new collaboration

Eyevensys Raises $12M in a Series B Plus Funding Round

 Eyevensys Raises $12M in a Series B Plus Funding Round 1920 1277 Eyevensys

Paris, France, and Cambridge, Mass., United States, August 04, 2021 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies..

Start Typing